{"protocolSection": {"identificationModule": {"nctId": "NCT00980785", "orgStudyIdInfo": {"id": "2014-1353"}, "secondaryIdInfos": [{"id": "H-2009-0036", "type": "OTHER", "domain": "UW Madison IRB"}, {"id": "A534255", "type": "OTHER", "domain": "UW, Madison"}, {"id": "SMPH/MEDICINE/GER-AD DEV", "type": "OTHER", "domain": "UW, Madison"}], "organization": {"fullName": "University of Wisconsin, Madison", "class": "OTHER"}, "briefTitle": "Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's", "officialTitle": "Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's", "acronym": "SEAIRA"}, "statusModule": {"statusVerifiedDate": "2020-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-04-09", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2011-07-26", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-07-26", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-09-18", "studyFirstSubmitQcDate": "2009-09-18", "studyFirstPostDateStruct": {"date": "2009-09-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-02-14", "resultsFirstSubmitQcDate": "2020-08-13", "resultsFirstPostDateStruct": {"date": "2020-08-25", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-08-13", "lastUpdatePostDateStruct": {"date": "2020-08-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Wisconsin, Madison", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Angiotensin converting enzyme inhibitors (ACE-I) are a group of blood pressure-lowering medicines. Some studies suggest that ACE-I, such as ramipril, may help prevent Alzheimer's disease (AD). The purpose of the research is to see how ramipril affects a substance in the body called beta-amyloid. Beta-amyloid is found in the brain and in the liquid around the brain and spinal cord. High amounts of beta-amyloid may be associated with a greater risk of getting Alzheimer's disease. This study will see if ramipril can lower the amount of beta-amyloid in the spinal fluid. This study will also see if ramipril affects blood vessel function and memory and thinking. The investigators hope that future studies will show whether ramipril might prevent memory loss and decrease the chance of developing Alzheimer's disease.", "detailedDescription": "High blood pressure (BP) in midlife is predictive of Alzheimer's disease (AD) in later life. Similarly, reductions in BP are associated with protection against AD. Treatment with antihypertensive medications, specifically angiotensin converting enzyme inhibitors (ACE-I) such as ramipril, is associated with up to a 55% reduction in the prevalence of AD, suggesting a potentially promising role for ACE-I in the prevention of AD. It is unknown however 1) whether ACE-Is will have the same effect on Cerebrospinal fluid (CSF) A\u03b2 levels in humans as in animal models 2) whether ACE-Is induce changes associated with vascular function (i.e. levels of CSF angiotensin converting enzyme (ACE) and peripheral endothelial function) and 3) whether there are interactions between ACE-I-induced changes in CSF A\u03b2, CSF ACE and indices of vascular function.\n\nOne mechanism by which antihypertensives may protect against AD is via A\u03b2 neuropathology. In order to better understand the mechanisms through which ACE-I may modify CSF A\u03b2 and possibly AD risk, we propose a randomized, double-blind, placebo-controlled pilot clinical trial, enrolling 20 middle-aged (age range 40 - 65 years), mildly hypertensive (between 130 - 160 mmHg mean systolic and between 85 - 100 mmHg mean diastolic) participants, who are adult children of an individual with AD. The main objective of this trial is to examine the effects of the ACE-I, ramipril, on 1) CSF A\u03b2 levels 2) CSF ACE levels and 3) peripheral endothelial function as measured by brachial artery flow-mediated vasodilation (FMD) and aortic augmentation index (AAIx), in middle-aged adults with mildly elevated BP, who are at increased risk of developing AD."}, "conditionsModule": {"conditions": ["Alzheimer's Disease", "Hypertension"], "keywords": ["Alzheimer's Disease", "Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "PREVENTION", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 14, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Matching Placebo", "interventionNames": ["Drug: Placebo"]}, {"label": "Active", "type": "EXPERIMENTAL", "description": "Ramipril 5mg/day", "interventionNames": ["Drug: Ramipril"]}], "interventions": [{"type": "DRUG", "name": "Ramipril", "description": "Ramipril 5 mg/day", "armGroupLabels": ["Active"], "otherNames": ["Altace"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching Placebo", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Cerebrospinal Fluid (CSF) Amyloid Beta-42 (A\u03b242) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo", "description": "CSF A\u03b242 levels will be measured from the cerebrospinal fluid taken from subjects on ramipril or placebo at the baseline visit and month 4 and will be measured by Dr. Henrik Zetterberg's laboratory.", "timeFrame": "Baseline to 4 months"}], "secondaryOutcomes": [{"measure": "Change in CSF Angiotensin Converting Enzyme (ACE) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo", "description": "CSF ACE levels will be measured from the cerebrospinal fluid taken from subjects on Ramipril or placebo at the baseline visit and month 4 and will be measured by ARUP\u00ae laboratories by spectrophotometric enzymatic assay.", "timeFrame": "Baseline to 4 months"}, {"measure": "Change in Flow-mediated Vasodilation (FMD) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo", "description": "FMD is calculated as the ratio of brachial artery diameter after reactive hyperemia to baseline diameter, expressed as percentage change. FMD for each subject (ramipril v placebo) will be measured at baseline and month 4, observing any differences.", "timeFrame": "Baseline to 4 months"}, {"measure": "Change in Augmentation Index (%) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo", "description": "Pulse wave velocity was measured using an AtCor SphymoCor Px tonometry system. A small pressure transducer was placed on the skin at the point the arterial pulsation of the right common carotid and right radial arteries. A Millar micromanometer is in the tip of the probe. Using a generalized transfer function, the distance between these pressure points, and the peripheral arterial waveforms, a central aortic pressure signal is derived, from which aortic augmentation index is determined.", "timeFrame": "Baseline to 4 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Between the ages of 40 and 65\n* Mean resting blood pressure between 130-160 systolic and 85-100 diastolic\n* Parent with Alzheimer's Disease\n\nExclusion Criteria:\n\n* Current involvement in another investigational drug trial.\n* Potassium \\> 5.0\n* Dementia based on DSMIV criteria\n* Mini-Mental State Exam (MMSE) score \\< 27\n* Current blood pressure medication (\\< 4 months from screening)\n* Weight loss medication\n* Contraindications for LP\n* Know diagnosis or history of hospitalization due to congestive heart failure\n* Elevated creatinine (females \\> 1.3 mg/dL or males \\> 1.4 mg/dL at baseline)\n* Diabetes Type I and II\n* Know adverse reaction to an ACE-I or an angiotensin receptor blocker\n* Pregnant of nursing women", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "40 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Cynthia M Carlsson, MD, MS", "affiliation": "University of Wisconsin, Madison", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Wisconisn Alzheimer's Disease Research Center", "city": "Madison", "state": "Wisconsin", "zip": "53705", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}]}, "referencesModule": {"references": [{"pmid": "22776970", "type": "BACKGROUND", "citation": "Wharton W, Stein JH, Korcarz C, Sachs J, Olson SR, Zetterberg H, Dowling M, Ye S, Gleason CE, Underbakke G, Jacobson LE, Johnson SC, Sager MA, Asthana S, Carlsson CM. The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. J Alzheimers Dis. 2012;32(1):147-56. doi: 10.3233/JAD-2012-120763."}], "seeAlsoLinks": [{"label": "Related Info", "url": "http://wisconsinadrc.wisc.edu/prevention_research.shtml"}, {"label": "The Effects of Ramipril in Individuals at Risk for Alzheimer's Disease: Results of a Pilot Clinical Trial", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593582/"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Participants were recruited from the Wisconsin Alzheimer's Disease Research Center (ADRC) registry and from the community for the clinical trial, Studying the Effects of Antihypertensives in Individuals at Risk for Alzheimer's (SEAIRA).", "groups": [{"id": "FG000", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo: Matching Placebo"}, {"id": "FG001", "title": "Active", "description": "Ramipril 5mg/day\n\nRamipril: Ramipril 5 mg/day"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo: Matching Placebo"}, {"id": "BG001", "title": "Active", "description": "Ramipril 5mg/day\n\nRamipril: Ramipril 5 mg/day"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "14"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "14"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "52.0", "spread": "6.7"}, {"groupId": "BG001", "value": "56.3", "spread": "6.1"}, {"groupId": "BG002", "value": "54.2", "spread": "6.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "14"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Cerebrospinal Fluid (CSF) Amyloid Beta-42 (A\u03b242) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo", "description": "CSF A\u03b242 levels will be measured from the cerebrospinal fluid taken from subjects on ramipril or placebo at the baseline visit and month 4 and will be measured by Dr. Henrik Zetterberg's laboratory.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/ml", "timeFrame": "Baseline to 4 months", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo: Matching Placebo"}, {"id": "OG001", "title": "Active", "description": "Ramipril 5mg/day\n\nRamipril: Ramipril 5 mg/day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-22.5", "spread": "78.7"}, {"groupId": "OG001", "value": "-31.71", "spread": "90.6"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Mann-Whitney test", "pValue": "0.836", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Mean Difference (Final Values)", "paramValue": "-22.5", "ciNumSides": "TWO_SIDED", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "78.7"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Mann-Whitney Test", "pValue": "0.836", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Mean Difference (Final Values)", "paramValue": "-31.71", "ciNumSides": "TWO_SIDED", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "90.6"}]}, {"type": "SECONDARY", "title": "Change in CSF Angiotensin Converting Enzyme (ACE) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo", "description": "CSF ACE levels will be measured from the cerebrospinal fluid taken from subjects on Ramipril or placebo at the baseline visit and month 4 and will be measured by ARUP\u00ae laboratories by spectrophotometric enzymatic assay.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "U/L", "timeFrame": "Baseline to 4 months", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo: Matching Placebo"}, {"id": "OG001", "title": "Active", "description": "Ramipril 5mg/day\n\nRamipril: Ramipril 5 mg/day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.10", "spread": "0.21"}, {"groupId": "OG001", "value": "-0.63", "spread": "0.32"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Mann-Whitney Test", "pValue": "0.009", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.10", "ciNumSides": "TWO_SIDED", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "0.21"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Mann-Whitney Test", "pValue": "0.009", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.63", "ciNumSides": "TWO_SIDED", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "0.32"}]}, {"type": "SECONDARY", "title": "Change in Flow-mediated Vasodilation (FMD) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo", "description": "FMD is calculated as the ratio of brachial artery diameter after reactive hyperemia to baseline diameter, expressed as percentage change. FMD for each subject (ramipril v placebo) will be measured at baseline and month 4, observing any differences.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage change", "timeFrame": "Baseline to 4 months", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo: Matching Placebo"}, {"id": "OG001", "title": "Active", "description": "Ramipril 5mg/day\n\nRamipril: Ramipril 5 mg/day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.70", "spread": "1.56"}, {"groupId": "OG001", "value": "-0.29", "spread": "1.23"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Mann-Whitney Test", "pValue": "0.755", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.70", "ciNumSides": "TWO_SIDED", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "1.56"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Mann-Whitney test", "pValue": "0.755", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.29", "ciNumSides": "TWO_SIDED", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "1.23"}]}, {"type": "SECONDARY", "title": "Change in Augmentation Index (%) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo", "description": "Pulse wave velocity was measured using an AtCor SphymoCor Px tonometry system. A small pressure transducer was placed on the skin at the point the arterial pulsation of the right common carotid and right radial arteries. A Millar micromanometer is in the tip of the probe. Using a generalized transfer function, the distance between these pressure points, and the peripheral arterial waveforms, a central aortic pressure signal is derived, from which aortic augmentation index is determined.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage change", "timeFrame": "Baseline to 4 months", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo: Matching Placebo"}, {"id": "OG001", "title": "Active", "description": "Ramipril 5mg/day\n\nRamipril: Ramipril 5 mg/day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.7", "spread": "8.9"}, {"groupId": "OG001", "value": "-1.8", "spread": "2.2"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Mann-Whitney test", "pValue": "0.491", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Mean Difference (Final Values)", "paramValue": "1.7", "ciNumSides": "TWO_SIDED", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "8.9"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Mann-Whitney test", "pValue": "0.491", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.8", "ciNumSides": "TWO_SIDED", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "2.2"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo: Matching Placebo", "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 0, "otherNumAtRisk": 6}, {"id": "EG001", "title": "Active", "description": "Ramipril 5mg/day\n\nRamipril: Ramipril 5 mg/day", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 0, "otherNumAtRisk": 8}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Limitations included small sample size, short duration of trial, and lack of A-beta neuropathology."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Cynthia M. Carlsson, MD, MS", "organization": "University of Wisconsin School of Medicine and Public Health", "email": "cmc@medicine.wisc.edu", "phone": "608-256-1901", "phoneExt": "11691"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2014-12-05", "uploadDate": "2020-08-13T18:09", "filename": "Prot_SAP_000.pdf", "size": 544305}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000000544", "term": "Alzheimer Disease"}, {"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000003704", "term": "Dementia"}, {"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}, {"id": "D000024801", "term": "Tauopathies"}, {"id": "D000019636", "term": "Neurodegenerative Diseases"}, {"id": "D000019965", "term": "Neurocognitive Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M3885", "name": "Alzheimer Disease", "asFound": "Alzheimer's Disease", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M6904", "name": "Dementia", "relevance": "LOW"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}, {"id": "M23002", "name": "Tauopathies", "relevance": "LOW"}, {"id": "M21558", "name": "Neurodegenerative Diseases", "relevance": "LOW"}, {"id": "M21836", "name": "Neurocognitive Disorders", "relevance": "LOW"}, {"id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW"}, {"id": "M4815", "name": "Mental Disorders", "relevance": "LOW"}, {"id": "T2192", "name": "Familial Alzheimer Disease", "asFound": "Alzheimer's Disease", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017257", "term": "Ramipril"}], "ancestors": [{"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000959", "term": "Antihypertensive Agents"}], "browseLeaves": [{"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M19553", "name": "Ramipril", "asFound": "Mandibular", "relevance": "HIGH"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}